The Liver Meeting 2023-Hans Popper State of the Art: Next Generation Human Liver Gene Therapy

Hans Popper State of the Art: Next Generation Human Liver Gene Therapy

Video Transcription

Video Summary

Dr. Holger Willenbring gave a presentation on next-generation liver gene therapy focusing on AAV vectors and their transduction efficiency in liver cells. Through experiments in mice and human liver tissue, he identified capsids that efficiently transduce hepatocytes, biliary epithelial cells, and other non-parenchymal liver cells. He discussed the potential of these findings for improving liver gene therapy, including targeting specific liver cell types for different diseases. He highlighted the implications for treating genetic liver diseases and potentially reprogramming ductal reactions in conditions like alcoholic hepatitis. Dr. Willenbring acknowledged the contributions of his team and collaborators, emphasizing the importance of their work in advancing liver gene therapy.

Keywords

Dr. Holger Willenbring

liver gene therapy

AAV vectors

transduction efficiency

hepatocytes

biliary epithelial cells

genetic liver diseases